Funding

Trailhead Biosystems

United States · Biotech

Develops human cells with defined molecular and functional properties for drug discovery and regenerative medicine

Visit trailbio.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Growth$20MMAK Capital — Role not disclosed

Investors

MAK CapitalGrowth

Coverage

Jan 12, 2026Trailhead Biosystems · Growth

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcestrailbio.com ↗